NEWS CENTER
Poseida News Center
Featured Content
Read media coverage on Poseida, find resources for the working press, and get insights from our executive leadership team on how Poseida is advancing a new class of cell and gene therapies.
Poseida in the News
Roche-Poseida Lead Allogeneic CAR-T Advances after Showing Promise in Multiple Myeloma
|
October 2, 2024
Coming Soon: An Off-the-Shelf CAR T Therapy for Myeloma
|
October 2, 2024
“Off-the-Shelf” CAR T Therapy Strikes Hard Against Relapsed Myeloma
|
September 30, 2024
P-BCMA-ALLO1 May Be Safe, Rapid, and Active Allogeneic CAR T-Cell Therapy in Pretreated R/R Myeloma
|
September 30, 2024
Poseida shares incremental Phase 1 update for Roche-partnered off-the-shelf CAR-T
|
September 30, 2024
The Allogeneic Future with Poseida’s Kristin Yarema, Ph.D.
|
August 5, 2024
Eight companies tackling cancer with allogeneic cell therapy in 2024
|
June 13, 2024
Top 10 Publicly Owned Gene Editing Therapy Companies
|
May 31, 2024
Executive Perspectives
Press Releases
Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche
|
October 17, 2024
Poseida Therapeutics Named to Newsweek’s List of the Top 200 America’s Most Loved Workplaces for 2024
|
October 3, 2024
Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients
|
September 27, 2024
Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma
|
September 16, 2024
Media Library
Usage rights & restrictions:
These media assets are free for editorial broadcast, print, online and radio use. They are restricted for other purposes.
